|
Characteristics
|
No MetS (NCEP-ATP III - / IDF -) (n = 1,608)
|
MetS (NCEP-ATP III +)
|
P
|
|---|
|
Total (n = 952)
|
With CeO (IDF +) (n = 804)
|
Without CeO (IDF -) (n = 148)
|
|---|
|
Age (years)
|
65 (60, 69)
|
64 (57, 69)
|
62 ± 8
|
61 ± 7
|
<0.001
|
|
Male gender (%)
|
31
|
36
|
32
|
62*
|
0.004
|
|
Smoking (%)
|
24
|
32
|
29
|
52*
|
<0.001
|
|
BMI (kg/m2)
|
24.0 ± 2.7
|
26.4 ± 2.9
|
26.8 ± 2.8
|
23.9 ± 1.9*
|
<0.001
|
|
Waist circumference (cm)
|
81 ± 8
|
89 ± 7
|
90 ± 7
|
81 ± 6*
|
<0.001
|
|
Heart rate (bpm)
|
66 ± 9
|
68 ± 10
|
68 ± 10
|
70 ± 11†
|
<0.001
|
|
SBP (mmHg)
|
120 ± 14
|
128 ± 15
|
128 ± 15
|
130 ± 15
|
<0.001
|
|
DBP (mmHg)
|
72 ± 9
|
77 ± 10
|
76 ± 10
|
79 ± 10†
|
<0.001
|
|
Antihypertensive medications (%)
|
29
|
66
|
67
|
66
|
<0.001
|
|
Total cholesterol (mg/dL)
|
201 ± 36
|
197 ± 37
|
197 ± 37
|
195 ± 36
|
0.006
|
|
Triglycerides (mg/dL)
|
94 (71, 118)
|
136 (103, 186)
|
164 ± 82
|
210 ± 80*
|
<0.001
|
|
HDL cholesterol (mg/dL)
|
57 (51, 63)
|
45 (37, 55)
|
47 ± 13
|
41 ± 11*
|
<0.001
|
|
LDL cholesterol (mg/dL)
|
110 (83, 127)
|
106 (83, 130)
|
121 ± 34
|
117 ± 33
|
0.096
|
|
Lipid lowering medications (%)
|
27
|
31
|
31
|
27
|
0.034
|
|
Creatinine (mg/dL)
|
0.78 (0.63, 0.95)
|
0.81 (0.68, 0.93)
|
0.79 ± 0.19
|
0.87 ± 0.19*
|
<0.001
|
|
Fasting glucose (mg/dL)
|
121 (105, 137)
|
125 (108, 143)
|
109 ± 24
|
114 ± 27‡
|
<0.001
|
|
Diabetes (%)
|
8
|
30
|
30
|
30
|
<0.001
|
|
Antidiabetic treatment (%)
|
7
|
25
|
82
|
84
|
<0.001
|
|
Duration of diabetes (months)
|
92 (44, 202)
|
92 (44, 152)
|
110 ± 85
|
107 ± 87
|
0.177
|
|
baPWV (cm/s)
|
1576 (1414, 1760)
|
1625 (1452, 1864)
|
1578 ± 270
|
1654 ± 315†
|
<0.001
|
- Continuous variables are expressed as mean ± SD or median [interquartile]. Categorical variables are presented as percentages. baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; CeO, central obesity; DBP, diastolic blood pressure; HDL, high-density lipoprotein; IDF, International Diabetes Federation; LDL, low-density lipoprotein; MetS, metabolic syndrome; NCEP-ATP III, National Cholesterol Education Program-Adult Treatment Panel III; SBP, systolic blood pressure. *p <0.001 vs. NCEP-ATP III + / IDF +, †p <0.01 vs. NCEP-ATP III + / IDF +, ‡p <0.05 vs. NCEP-ATP III + / IDF +.
